Protara Therapeutics Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Protara Therapeutics Inc.
- Former names
- ArTara Therapeutics, Inc. Proteon Therapeutics Inc
- Ownership
- Public
- Status
- Active
- SIC code
- 2836 — Biological Products, (No Diagnostic Substances)
- Headquarters city
- New York
- Headquarters state / province
- New York
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- TARA
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001359931
- EIN
- 20-4580525
Board of directors
-
Barry P. Flannelly · DirectorSince 2023
- Since 2023
-
Gregory Sargen · DirectorSince 2023
-
Jane Huang · DirectorSince 2023
-
Jesse Shefferman · Director · CEO and PresidentSince 2023
-
Luke M. Beshar · DirectorSince 2023
-
Michael Edward Solomon · DirectorSince 2023
-
Richard S. Levy · DirectorSince 2023
-
Roger Garceau · DirectorSince 2023
Chief executives
Jesse Shefferman
· CEO and President
Dates unknown
Director election results
Annual meeting of June 12, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
72.4%
-
86.3%
Board connections
3 of this board's directors also sit on 8 other boards.
- via Cynthia Smith
- via Cynthia Smith
- via Roger Garceau
- via Richard S. Levy
- via Richard S. Levy
- via Richard S. Levy
- via Cynthia Smith
- via Cynthia Smith
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $1,007,149
- 3 sales by 2 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jun 30, 2026 | Jesse Shefferman Director, Officer (CEO and President) | Gift | −14,000 | — | — |
| Jun 30, 2026 | Jesse Shefferman Director, Officer (CEO and President) | Gift | −7,000 | — | — |
| Jun 30, 2026 | Jesse Shefferman Director, Officer (CEO and President) | Gift | −4,000 | — | — |
| Jun 30, 2026 | Jesse Shefferman Director, Officer (CEO and President) | Gift | −5,000 | — | — |
| Jun 29, 2026 | Jesse Shefferman Director, Officer (CEO and President) | Option exercise | +215,687 | $1.91 | $411,962 |
| Jun 29, 2026 | Jesse Shefferman Director, Officer (CEO and President) | Open-market sale | −215,687 | $4.09 | $882,160 |
| Jun 2, 2026 | William Conkling Officer (Chief Commercial Officer) | Shares withheld for tax | −6,008 | $4.34 | $26,075 |
| Apr 8, 2026 | Zummo Jacqueline Officer (Chief R&D Officer) | Open-market sale | −1,134 | $5.40 | $6,124 |
| Apr 1, 2026 | Zummo Jacqueline Officer (Chief R&D Officer) | Open-market sale | −22,598 | $5.26 | $118,865 |
| Jan 26, 2026 | Jesse Shefferman Director, Officer (CEO and President) | Shares withheld for tax | −8,732 | $6.67 | $58,242 |
| Jan 26, 2026 | Zummo Jacqueline Officer (Chf Scientific Operations Off) | Shares withheld for tax | −3,724 | $6.67 | $24,839 |
| Jan 26, 2026 | Fry Hannah Officer (VP, Controller) | Shares withheld for tax | −1,457 | $6.67 | $9,718 |
| Jan 26, 2026 | Patrick Fabbio Officer (Chief Financial Officer) | Shares withheld for tax | −3,261 | $6.67 | $21,751 |
| Jan 20, 2026 | Jesse Shefferman Director, Officer (CEO and President) | Shares withheld for tax | −16,322 | $5.60 | $91,403 |
| Jan 20, 2026 | Patrick Fabbio Officer (Chief Financial Officer) | Shares withheld for tax | −3,063 | $5.60 | $17,153 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.